Madison Medical Center | |
611 West Main Street, Po Box 431, Fredericktown, Missouri 63645 | |
(573) 783-3341 | |
Name | Madison Medical Center |
---|---|
Location | 611 West Main Street, Po Box 431, Fredericktown, Missouri |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 119 |
Occupancy Rate | 44.87% |
Medicare ID (CCN) | 265561 |
Legal Business Name | Madison Medical Center Stockhoff Memorial Nursing Home |
Ownership Type | Government - City/county |
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Elsevier, a world-leading provider of scientific, technical and medical information products and services, has announced that it has been selected by the Society of Obstetricians and Gynaecologists of Canada to publish its journal, Journal of Obstetrics and Gynaecology Canada, as of January 2016.
St James's Institute of Oncology, a leading radiotherapy center in the UK, recently ordered two Versa HD™ systems, an advanced linear accelerator designed to improve patient care and treat a wide range of tumors throughout the body.
Annual computed tomography (CT) screening identifies a high proportion of patients with early-stage lung cancer, according to the latest findings of the NewYork-Presbyterian Hospital/Weill Cornell Medical Center - led New York Early Lung Cancer Action Project (NY-ELCAP) published in the April issue of the journal Radiology.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 14.73 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.55 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 41.91 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.4 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.5 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.43 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.81 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.61 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 10.79 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 85.71 | 83.88 |